Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells

被引：0
|
作者：
Amjad Ali
Hema Unnikannan
Jasmin Shafarin
Khuloud Bajbouj
Jalal Taneera
Jibran Sualeh Muhammad
Haydar Hasan
Albert Salehi
Samir Awadallah
Mawieh Hamad
机构：
[1] University of Sharjah,Sharjah Institute for Medical Research
[2] University of Sharjah,Department of Basic Medical Sciences, College of Medicine
[3] University of Sharjah,Department of Clinical Nutrition and Dietetics, College of Health Sciences
[4] Lund University,Department of Clinical science, UMAS, Clinical Research Center
[5] University of Gothenburg,Department of Neuroscience and Physiology, Metabolic Research Unit
[6] University of Sharjah,Department of Medical Laboratory Sciences, College of Health Sciences
来源：
Endocrine | 2022年 / 76卷
关键词：
Metformin; PCSK9; HNF-1α; SREBP2; LDL-cholesterol; LDLR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [31] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
    Xuhui Bao
    Yongjun Liang
    Hanman Chang
    Tianji Cai
    Baijie Feng
    Konstantin Gordon
    Yuekun Zhu
    Hailian Shi
    Yundong He
    Liyi Xie
    Signal Transduction and Targeted Therapy, 9
  • [32] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
    O'Connell, Emma M.
    Lohoff, Falk W.
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [33] Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis
    Lu, Xinjie
    CURRENT DRUG TARGETS, 2019, 20 (10) : 1029 - 1040
  • [34] Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum
    Jabor, Antonin
    Vackova, Tereza
    Kubicek, Zdenek
    Komrskova, Jitka
    Protus, Marek
    Franekova, Janka
    CLINICA CHIMICA ACTA, 2021, 521 : 59 - 63
  • [35] PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
    Shimada, Yuichi J.
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL, 2015, 36 (36) : 2415 - U36
  • [36] Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
    Bhattacharya, Anindita
    Chowdhury, Abhirup
    Chaudhury, Koel
    Shukla, Praphulla Chandra
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (01):
  • [37] Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel psoriasis susceptibility locus
    Merleev, A.
    Toussi, A.
    Downing, L.
    Tran, M.
    Nava, J.
    Le, S.
    Marusina, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S1 - S1
  • [38] Involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in aortic valvular calcification
    Poggio, P.
    Songia, P.
    Chiesa, M.
    Barbieri, S.
    Moschetta, D.
    Valerio, V.
    Cavallotti, L.
    Ferri, N.
    Zanotti, I.
    Camera, M.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1057 - 1057
  • [39] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value
    Tice, Jeffrey A.
    Kazi, Dhruv S.
    Pearson, Steven D.
    JAMA INTERNAL MEDICINE, 2016, 176 (01) : 107 - 108
  • [40] Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
    Grewal, Thomas
    Buechler, Christa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
12345